Precigen, Inc. (NASDAQ:PGEN) Short Interest Update

Precigen, Inc. (NASDAQ:PGEN) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totaling 35,580,646 shares, an increase of 28.2% from the December 15th total of 27,758,985 shares. Approximately 19.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 6,911,562 shares, the short-interest ratio is presently 5.1 days. Based on an average daily trading volume, of 6,911,562 shares, the short-interest ratio is presently 5.1 days. Approximately 19.0% of the shares of the stock are short sold.

Precigen Trading Up 6.5%

NASDAQ:PGEN traded up $0.27 on Monday, hitting $4.41. 3,636,852 shares of the stock were exchanged, compared to its average volume of 4,749,462. The stock has a market capitalization of $1.56 billion, a price-to-earnings ratio of -3.17 and a beta of 1.10. Precigen has a 52 week low of $1.08 and a 52 week high of $5.22. The company has a debt-to-equity ratio of 2.22, a quick ratio of 3.95 and a current ratio of 4.04. The company’s 50-day moving average price is $4.08 and its 200 day moving average price is $3.46.

Precigen (NASDAQ:PGEN) last issued its earnings results on Thursday, November 13th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The business had revenue of $2.92 million during the quarter, compared to the consensus estimate of $0.67 million. Precigen had a negative net margin of 3,912.92% and a positive return on equity of 1,066.10%. On average, equities research analysts forecast that Precigen will post -0.32 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Randal J. Kirk sold 1,900,036 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $4.18, for a total transaction of $7,942,150.48. Following the sale, the director owned 341,189 shares in the company, valued at approximately $1,426,170.02. This represents a 84.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 4,866,329 shares of company stock worth $20,233,899 over the last quarter. 47.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Precigen

Several institutional investors and hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd acquired a new position in shares of Precigen in the 3rd quarter valued at $39,000. Russell Investments Group Ltd. bought a new stake in Precigen in the third quarter valued at about $41,000. Asempa Wealth Advisors acquired a new position in Precigen in the fourth quarter valued at about $48,000. Vontobel Holding Ltd. bought a new position in Precigen during the third quarter worth about $48,000. Finally, CIBC Bancorp USA Inc. acquired a new position in shares of Precigen during the 3rd quarter worth about $53,000. Institutional investors own 33.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on PGEN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research report on Wednesday, October 8th. HC Wainwright boosted their target price on shares of Precigen from $8.50 to $9.00 and gave the stock a “buy” rating in a research note on Friday, November 14th. Finally, Wall Street Zen lowered shares of Precigen from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.